Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2010

View Archived Issues

Combined GM-CSF and agatolimod arm melanoma sentinel lymph nodes against metastasis

Thymosin beta4 safe in phase II corneal wound-healing study

Stable disease noted in non-small cell lung cancer patients given HyperAcute-Lung cancer vaccine

Novel parathyroid hormone secretion inhibitors claimed by Amgen

NeuroSearch discovers novel nAChR alpha7 modulators

Novel antimalarial agents disclosed by French researchers

Amgen describes novel p38alpha MAPK inhibitors

DAS-181 trial in asthmatics initiated at the National Institutes of Health

Novel anti-CD27 antibody displays preclinical potential in cancer therapy

Anthera reports additional data from FRANCIS study

AdventRx presents 6-month stability data for ANX-530

Corcept updates Corlux program in Cushing's syndrome

Prolor reports preclinical data for enhanced biological activity potential of pipeline

INNO-206 shrinks human tumors in an animal model of multiple myeloma

Stason to develop and commercialize Peregrine's tumor necrosis therapy in APEC countries

Cadence resubmits NDA for Ofirmev

Synageva BioPharma files for orphan drug designation for SBC-102

Cinacalcet allows lower doses of calcitriol and phosphate for X-linked hypophosphatemia

Santen licenses ATL-313 from Clinical Data to develop topical treatment for ophthalmic diseases

Phase II results show TZP-101 efficacy in severe gastroparesis

Novel therapeutic vaccine for latent tuberculosis starts phase II clinical trials

Pharmasset reports phase IIa results for PSI-7977 in chronic hepatitis C patients

FDA conducts safety review of GnRH agonist use in men with prostate cancer

S*BIO and Onyx expand collaboration agreement for JAK2 inhibitors

Anavex reports results from animal studies of new Alzheimer's treatment

FDA requests additional clinical trial in complete response letter to InterMune on Esbriet NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...